XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke
Retrieved on:
Tuesday, July 14, 2020
The publication titled, Post-Ischemic Administration of IL-1a Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke , points to a use for XBiotechs drug candidate antibody that blocks interleukin-1 alpha (IL-1) for use as a therapeutic to reduce brain damage and neurological deficit after stroke.
Key Points:
- The publication titled, Post-Ischemic Administration of IL-1a Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke , points to a use for XBiotechs drug candidate antibody that blocks interleukin-1 alpha (IL-1) for use as a therapeutic to reduce brain damage and neurological deficit after stroke.
- Dr. Camicis research team tested an anti-IL-1 antibody provided by XBiotech to evaluate its ability to reduce brain injury in animals subjected to an experimental stroke and reperfusion injury.
- Dr. Camicis research team focused on a particular difficult aspect of ischemic stroke, so called reperfusion injury.
- When patients suffer from a stroke, or a blockage in an artery that provides crucial blood and oxygen to the brain, a portion of the brain typically suffers irreparable damage.